NCIC CLINICAL TRIALS GROUP – GI DISEASE SITE COMMITTEE

PANCREAS
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO
DATE SATURDAY, MAY 2nd, 2015
TIME: 11:15 - 12:30
CHAIRS: DR. STEVE GALLINGER, DR. DANIEL RENOUF

11:15 WELCOME AND INTRODUCTION/MEMBERSHIP UPDATE
DR. S. GALLINGER/DR. D. RENOUF

11:15 OPEN TRIALS

PA.6 (ACCORD 24): RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA
DR. A. WEI / DR. J. BIAGI

11:25 TRIALS/CONCEPTS IN DEVELOPMENT

ALLIANCE 021101: NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE_ARM PILOT STUDY
DR. A. WEI/DR. S. GALLINGER

SWOG 51505: FOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL AS NEOADJUVANT THERAPY FOR RESECTABLE PANCREATIC ADENOCARCINOMA: A RANDOMIZED PHASE II STUDY
DR. D. RENOUF

PHASE II TRIAL OF FOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRCA WT PANCREASE CANCER
DR. D. RENOUF

11:55 INTERGROUP TASK FORCE UPDATE
DR. D. RENOUF

12:05 DISCUSSION – NON-TRIAL ISSUES
DR. S. GALLINGER

CLOSING REMARKS